Lars Verschuren
My work focuses on the development of mechanism‑driven biomarkers for early disease detection and clinical decision‑making. I primarily focus on fibrotic and metabolic diseases, where I integrate multi‑omics, systems biology, and clinical data to develop biomarkers that are directly applicable in research and healthcare.
‘A biomarker only matters if it changes a decision.’
I am involved in challenges related to early diagnostics of metabolic and fibrotic diseases, with a strong focus on MASLD/MASH and liver fibrosis. In this context, I develop and validate mechanism‑driven biomarker panels based on multi‑omics data, aiming to deliver biomarkers that directly support clinical or preventive decision‑making. I enjoy working at the interface of fundamental biology, clinical application, and diagnostic innovation within public–private collaborations.
My core activities include designing and leading biomarker development trajectories from discovery to clinical validation, integrating multi‑omics data with clinical cohorts, and benchmarking novel biomarkers against existing Non‑Invasive Tests (NITs). In addition, I coordinate national and international consortia and support valorisation and implementation pathways towards healthcare and the market.
Please feel free to get in touch to explore how we can jointly develop biomarkers that make a real difference in research, healthcare, and prevention.
Relevant links:
- TNO discovers new method to diagnose liver disease
- Functional biomarkers
- Development of TLM3 for hepatic fibrosis in MASLD (EN)
- Genepanel for the early prediction of pharmaceutical efficacy (EN)
- Prognostic value of TLM3 in early fibrosis developments in general population (pdf) (EN)
- Snellere behandeling voor leverziekten - TO2 (NL)
Leiden - Sylviusweg
Sylviusweg 71
2333 BE Leiden
The Netherlands